Table of Contents
The potential offered by biomarkers in shaping the outcomes of clinical trials, identifying new drug targets and developing diagnostic assays for detecting diseases early is immense, which has ensued in a large number of scientific publications coming out over the past two decades. Biomarker research encompasses widespread fields of discipline, which comprise drug discovery, toxicity, clinical markers of efficacy and therapeutic indicators, development of diagnostic assays and environmental pollutant exposure. The fields of epidemiology and toxicology have also made use of biomarkers in indicating exposure to a range of environmental substances. In such instances, the biomarker could be the substance itself, such as asbestos particles or nicotine-derived nitrosamine ketone (NNK) from tobacco, or a variation of the external substance processed by the body, such as a metabolite. Using biomarkers in species, such as aquatic animals and invertebrates can be helpful in determining levels and ranges of environmental pollutants.
Personalized medicine constitutes another facet that has been in an ever increasing mode, wherein genomic data are utilized for classifying subsets of patients that would respond to a specific line of therapy. The progression of biomarker research in ascertaining the basics of personalized medicine implies that the prospects of jointly developing drugs and biomarkers would be associated with identifying that section of the population that would garner the maximum benefit from that drug treatment. Developing such biomarkers requires expending considerable efforts and resources, which would enable in expanding the tasks accomplished by biomarkers in disease screening as surrogate endpoints and diagnostic indices.
Biomarker discovery techniques analyzed in this report include Bioimaging, Bioinformatics and Omics Technologies. On a broader geographic level, these technologies further drilled down to Bioimaging – Computed Tomography (CT), Magnetic Resonence Imaging (MRI), Ultrasound and Other; and Omics Technologies – Genomics, Metabolomics, Proteomics and Other. The study also explores the global market for therapeutic areas of biomarkers comprising Cardiology, Neurology, Oncology and Other.
The report reviews, analyses and projects the Biomarkers market for global and the regional markets including the United States, Europe, Asia-Pacific and Rest of World. The regional markets further analyzed for 10 independent countries across Europe – France, Germany, Italy, Spain, Sweden, the United Kingdom; and Asia-Pacific – Australia, China, India and Japan. Accounting for a lion’s share of an estimated 47% in 2013, equating to US$18.9 billion, the United States leads the global market for Biomarkers. Growing at a robust compounded annual growth rate of 18.8% during the period 2013-2020, the global market is projected to touch US$63.2 billion.
This 350 pages, global market report includes 100 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of market numbers. The statistical tables represent the data for the market value in US$ by geographic region, biomarker discovery techniques and therapeutic area. This report profiles 52 key global players and 70 major players across the United States – 34; Europe – 24; Asia-Pacific – 7 and Rest of World - 5. The research also provides the listing of the companies engaged in research & development, equipment manufacturing and supply of biomarkers. The global list of companies covers addresses, contact numbers and the website addresses of 245 companies.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
Global Non-alcoholic Steatohepatitis Biomarker Market: Overview Non-alcoholic steatohepatitis (NASH) is liver disease which is categorized under the spectrum of non-alcoholic fatty liver disease (NAFLD). ...
The global biomarkers market is estimated to reach USD 53.34 billion by 2021 from USD 27.95 billion in 2016, at a CAGR of 13.8% from 2016 to 2021. Increasing diagnostic applications of biomarkers, increasing ...
The global next-generation sequencing market is estimated to register a CAGR of 20.5% from 2017 to 2022 to reach USD 12.45 billion by 2022. Factors such as technological advancements in NGS platforms, ...